In Short
The Development: On July 13, 2026, the Federal Trade Commission ("FTC") announced a proposed settlement with Edwards Lifesciences Corp. ("Edwards") and Genesis MedTech Group Limited ("Genesis"), resolving allegations that the companies violated the Hart-Scott-Rodino ("HSR") Act by failing to report Edwards's proposed acquisition of Genesis's subsidiary JC Medical, Inc. ("JC Medical"). Edwards and Genesis will pay civil penalties of $10 million and $2 million, respectively.
The Context: The government alleges that Edwards structured the transaction to remain below the then-applicable $119.5 million HSR threshold by pairing the cash purchase price with a simultaneous investment in Genesis. The complaint alleges that the Genesis investment was part of the same deal and that sufficient value from that investment should have been attributed to JC Medical, making the transaction reportable.